Shruti Bhat PhD, MBA, Lean Six Sigma Black Belt
  • Home
  • About Shruti
  • Consulting
  • Workshops
  • Patents
  • Articles
    • Case Studies
    • Innovation Portfolio Development & Patents
    • Drugs-in-the- making
    • Culture Change & Business Transformation
    • Operational Excellence, Quality & Continuous Improvement
  • Books
  • Digital
  • Blog
  • Videos
  • Contact

Drug Research updates

1/7/2010

0 Comments

 
WHO says Tamiflu-resistant cases call for "vigilant monitoring."
The recent reports of Tamiflu resistance has prompted the World Health Organization to recommend "boosted antiviral treatment for hospital patients with severely weakened immune systems who contract swine flu." WHO maintained that there had been "no evidence" that the reported cases represented a wider public health threat, but "reiterated calls for vigilance and modified treatment advice for the frontline flu drug."  

Cervarix may protect against HPV for more than six years.
Cervarix, one of two FDA-approved vaccines against human papillomavirus (HPV), protects against infection for more than six years, researchers found." In a Lancet paper, researchers reported that through "follow-up as long as 6.4 years, the vaccine had an efficacy of 95.3% for preventing infection with the two types of HPV most commonly implicated in cervical cancer -- HPV-16 and -18." In addition, Cervarix was found to be "100% effective at preventing cases of cervical intraepithelial neoplasia grade 1 and above, the investigators reported."  

“Wellness" blog also notes that previous "research has shown that the equivalent vaccine, Gardasil, from fellow pharmaceutical giant Merck, protects for up to five years."

Novavax H1N1 vaccine study seen as meeting goals.
Novavax Inc. announced that its H1N1 flu vaccine proved safe and effective in a study conducted in Mexico." Novavax "said that the vaccine, which uses lab-created virus-like particles rather than the entire live virus strain, produced favorable initial results from the first stage of a two-stage pivotal Phase II study." Based on the findings, the company also "said it has been cleared to proceed to a second stage of testing in which vaccine safety will be evaluated in 3,000 subjects with a single dose regimen." An independent panel said the vaccine was well tolerated at three dose levels and showed no systemic side effects.

Lenalidomide plus bortezomib may be promising for relapsed, refractory multiple myeloma.
Lenalidomide (Revlimid) combined with bortezomib (Velcade) appears to be a promising treatment for patients with relapsed and refractory multiple myeloma," according to a study published in the Journal of Clinical Oncology. Researchers found that "overall, the combination treatment was well tolerated." But, in an accompanying editorial, Jesús F. San Miguel, MD, of the University of Salamanca in Spain, noted that "similar results have been observed with combination therapy that includes bortezomib, cyclophosphamide, and dexamethasone, or lenalidomide, doxorubicin, and dexamethasone," which "could be considered as an...argument in favor of the sequential rather than simultaneous use of bortezomib and lenalidomide."
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement

    New Book Released!

    top ten strategic decision-making tools for operational excellence

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    5S
    Agile
    Artificial Intelligence
    Automation
    Balanced Score Card
    Biotechnology
    Books
    Business Turnaround
    Case Studies
    Change Management
    Chemical Industry
    CMMI
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Food Industry
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    Nanotechnology
    Operations
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    Robotics
    Scrum
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    TQM
    Videos
    Voice Of Customer
    Workshops

    Shruti's books...

    Picture
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    Picture
    how to overcome challenges of creating effective teams
    how to lead a successful business transformation

    ​Micro-Learning
    ​Partner

    Picture

    Publishing Partner

    fast read books, business management books, health and wellness books, spiritual guidance books, best online book store

    Wellness
    ​Partner

    Picture
© Copyright 1992- 2022 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media